Skip to main content
. 2022 Apr;13(3):287–293. doi: 10.1016/j.jgo.2021.12.009

Table 2.

Baseline patient characteristics.

X. Total
(N = 514)
Age (years)
 Median [Min, Max] 76.0 [51.0, 96.0]



Sex
 Male 385 (74.9%)
 Female 129 (25.1%)



Histology
 Squamous 57 (11.1%)
 Non-squamous 457 (88.9%)



Metastases
 Yes 347 (67.5%)
 No 167 (32.5%)



Planned use of Trastuzumab
 Yes 28 (5.4%)
 No 486 (94.6%)



Dose reduction due to renal/hepatic function
 Yes 45 (8.8%)
 No 469 (91.2%)